Lab services and equipment provider Agilent Technologies will acquire Prince Edward Island-based CDMO Biovectra in a deal worth $925 million.
According to Agilent, the deal will help build on its CDMO specialization in oligonucleotides and CRISPR therapeutics. Agilent's oligo contract manufacturing business currently produces six commercially-approved API molecules at the company's two facilities in Colorado.
The acquistion will give Agilent Biovectra's sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle formulation capabilities. Biovectra also brings expertise in fast-growing modalities, including ADCs, HPAPIs and GLP-1s, as well as gene editing.
Once a Mallinckrodt subsidiary, BioVectra — along with its workers and facilities — was sold off to an affiliate of H.I.G. Capita for approximately $250 million in 2019.
